Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 9.52 is in line with its 5-year average of 9.19, near the low end of its 5-year range (2.40–33.20).
As of the fiscal period ended Tuesday, June 30, 2026. 22.48% above its 12-month average of 7.78.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.52.
CURRENT RATIO
9.52
CURRENT RATIO AVG TTM
7.78
CURRENT RATIO AVG 3Y
6.80
CURRENT RATIO AVG 5Y
9.19
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+22.48%
CURRENT VS 3Y AVG
+40.11%
CURRENT VS 5Y AVG
+3.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.73
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+155.69%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$836.98M
Current Ratio
9.52
TTM Avg
7.78
3Y Avg
6.80
5Y Avg
9.19
Market Cap
$840.85M
Current Ratio
25.06
TTM Avg
12.67
3Y Avg
12.67
5Y Avg
12.67
Market Cap
$844.84M
Current Ratio
4.92
TTM Avg
7.19
3Y Avg
6.36
5Y Avg
8.34
Market Cap
$849.66M
Current Ratio
1.39
TTM Avg
1.36
3Y Avg
1.46
5Y Avg
2.28
Market Cap
$855.16M
Current Ratio
3.05
TTM Avg
43.83
3Y Avg
35.58
5Y Avg
35.58
Market Cap
$860.37M
Current Ratio
1.95
TTM Avg
2.27
3Y Avg
2.05
5Y Avg
2.13
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $836.98M | 9.52 | 7.78 | 6.80 | 9.19 |
| Beta Bionics, Inc. (BBNX)vs › | $839.06M | 8.88 | 7.47 | 6.98 | 6.98 |
| Alumis Inc. (ALMS)vs › | $833.76M | 6.74 | 5.17 | 5.15 | 5.15 |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.85M | 25.06 | 12.67 | 12.67 | 12.67 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $844.84M | 4.92 | 7.19 | 6.36 | 8.34 |
| QuidelOrtho Corporation (QDEL)vs › | $849.66M | 1.39 | 1.36 | 1.46 | 2.28 |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | 3.05 | 43.83 | 35.58 | 35.58 |
| SI-BONE, Inc. (SIBN)vs › | $860.28M | 9.15 | 8.11 | 7.93 | 9.72 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $860.37M | 1.95 | 2.27 | 2.05 | 2.13 |
| Ardelyx, Inc. (ARDX)vs › | $810.26M | 3.34 | 4.45 | 4.03 | 4.25 |
Current Ratio
9.52
Quick Ratio
9.52
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 9.52 |
| 2026-03-31 | 9.54 |
| 2025-12-31 | 6.12 |
| 2025-09-30 | 6.54 |
| 2025-06-30 | 7.16 |
| 2025-03-31 | 5.61 |
| 2024-12-31 | 2.40 |
| 2024-09-30 | 6.03 |
| 2024-06-30 | 6.56 |
| 2024-03-31 | 4.82 |
| 2023-12-31 | 5.07 |
| 2023-09-30 | 8.09 |
| 2023-06-30 | 10.90 |
| 2023-03-31 | 11.73 |
| 2022-12-31 | 10.79 |
| 2022-09-30 | 13.55 |
| 2022-06-30 | 20.11 |
| 2022-03-31 | 25.65 |
| 2021-12-31 | 20.96 |
| 2021-09-30 | 29.08 |
| 2021-06-30 | 33.20 |
| 2021-03-31 | 18.89 |
| 2020-12-31 | 1.49 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
